170 related articles for article (PubMed ID: 36551247)
21. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
22. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
24. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
25. Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.
Maxwell KN; Soucier-Ernst D; Tahirovic E; Troxel AB; Clark C; Feldman M; Colameco C; Kakrecha B; Langer M; Lieberman D; Morrissette JJD; Paul MR; Pan TC; Yee S; Shih N; Carpenter E; Chodosh LA; DeMichele A
Breast Cancer Res Treat; 2017 Aug; 164(3):627-638. PubMed ID: 28500398
[TBL] [Abstract][Full Text] [Related]
26. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
27. Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.
Rudlowski C; Beermann N; Leitzen L; Nuding B
Breast Care (Basel); 2020 Jun; 15(3):289-293. PubMed ID: 32774224
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
29. Use of Liquid Biopsy to Detect PIK3CA Mutation in Metastatic Breast Cancer.
Nakai M; Yamada T; Sekiya K; Sato A; Hankyo M; Kuriyama S; Takahashi G; Kurita T; Yanagihara K; Yoshida H; Ohashi R; Takei H
J Nippon Med Sch; 2022 Mar; 89(1):66-71. PubMed ID: 33692304
[TBL] [Abstract][Full Text] [Related]
30. Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing.
Kleftogiannis D; Ho D; Liew JX; Poon PSY; Gan A; Ng RC; Tan BK; Tay KH; Lim SH; Tan GS; Shih CC; Lim TK; Lee AS; Tan IB; Yap YS; Ng SB
Sci Rep; 2020 Oct; 10(1):16774. PubMed ID: 33033274
[TBL] [Abstract][Full Text] [Related]
31. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
32. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
33. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Hart L; Campone M; Petrakova K; Winer EP; Janni W; Conte P; Cameron DA; André F; Arteaga CL; Zarate JP; Chakravartty A; Taran T; Le Gac F; Serra P; O'Shaughnessy J
N Engl J Med; 2022 Mar; 386(10):942-950. PubMed ID: 35263519
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
[TBL] [Abstract][Full Text] [Related]
35. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Sim SH; Yang HN; Jeon SY; Lee KS; Park IH
Sci Rep; 2021 Mar; 11(1):5566. PubMed ID: 33692409
[TBL] [Abstract][Full Text] [Related]
36. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
37. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
38. Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer.
Cardinali B; De Luca G; Tasso R; Coco S; Garuti A; Buzzatti G; Sciutto A; Arecco L; Villa F; Carli F; Reverberi D; Quarto R; Dono M; Del Mastro L
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682999
[TBL] [Abstract][Full Text] [Related]
39. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
40. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
